Abu Dhabi Launches AstraZeneca-Oracle Partnership

AstraZeneca announced its collaboration with Oracle to utilize artificial intelligence and real-world data in identifying suitable patients for clinical trials and monitoring safety indicators, with the aim of improving its clinical research. The partnership will initially focus on cancer, cardiovascular and respiratory diseases, immune disorders, and rare diseases, and may support early diagnosis of serious illnesses. This collaboration will help reduce the challenges of patient recruitment, which often lead to delays, longer trial timelines, and increased costs. AstraZeneca aims to expand its drug portfolio and achieve annual revenues exceeding $80 billion by 2030, with a focus on enhancing innovation in clinical research through advanced technologies.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل